FREE PROMEGA WEBINAR
Date : 6thOctober 2022
Time : 11 am (Indonesia)
otency assays are an essential aspect of analyses of biotherapeutics, including CAR-T therapeutics. The potency assay format that will be used as a release assay for CT (in a QC environment) needs to be as accurate, precise and robust as possible. Developing a robust potency assay for CART therapeutics can be a long and complicated process. The mechanism of action of CAR-T cells – dubbed ‘living drugs* – in-vivo is multi-faceted.
Currently, target-cell killing and cytokine induction are two of the more prominent measures indicative of CAR-T potency in the cell therapy field. This webinar will provide the rationale and data that supports transitioning from current interpolation-based cytokine induction assays, with minimal number of dilutions (one), to full-curve analyses based upon MOA-reflective cellular responses.
In this webinar, you will lean more about :
• Limitations of existing CAR-T potency measurement approaches
• A new HiBiT target-cell killing based approach for CAR-T potency assessment
Link Webinar: https://bit.ly/3CnYcu5
